Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Johansson, Inger ^a   Mårtensson, Gunnar ^a   Nyström, Ulla ^b   Nasic, Salmir ^c   Andersson, Rune ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c SKARABORG HOSPITAL   (Sweden)

Author keywords

Bronchiolitis obliterans syndrome; Cytomegalovirus; Ganciclovir; Lung transplantation; Survival rates; Valganciclovir

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; BRONCHIOLITIS OBLITERANS; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; HYPOXIA; INCIDENCE; LONG TERM SURVIVAL; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; SCHOOL CHILD; SERODIAGNOSIS; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; BRONCHIOLITIS OBLITERANS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GRAFT REJECTION; HUMANS; INCIDENCE; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84889858573     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-582     Document Type: Article

References (28)

1. Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl Infect Dis 2001, 3:128-137.
2. Fishman AJ, Emery V, Freeman R, Pascual M, Rostaing L, Schlitt HJ, Sgarabotto D, Torre-cisneros J, Uknis ME. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007, 21:149-158.
3. Snydman DR, Limaye AP, Potena L, Zamora MR, Weigand K. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc 2011, 43:S1-S17.
4. Johanssson I, Mårtensson G, Andersson R. Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden. Scand J Infect Dis 2010, 42:129-136.
5. Zuk DM, Humar A, Weinkauf JG, Lien DC, Nador RG, Kumar D. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation 2010, 90:672-676.
6. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, O'Grady J, Robinson C, To Z, Wren K, Banken L, Buhles W, Brown F. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000, 44:2811-2815.
7. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz MI. The registry of the international society for heart and lung transplantation: twenty-eighth adult lung and heart-lung transplant report-2011. J Heart Lung Transplant 2011, 30:1104-1122.
8. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GB, Snell GI, Yousem S. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002, 21:297-310.
9. Zamora MR. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation. Transpl Infect Dis 2001, 3:49-56.
10. Todd JL, Palmer SM. Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. Chest 2011, 140:502-508.
11. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010, 181:1391-1396.
12. Parada MT, Alba A, Sepúlveda C. Bronchiolitis obliterans syndrome development in lung transplantation patients. Transplant Proc 2010, 42:331-332.
13. Paraskeva M, Bailey M, Levvey BJ, Griffiths AP, Kotsimbos TC, Williams TP, Snell G, Westall G. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 2011, 11:2190-2196.
14. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
15. Husain AN, Siddiqui MT, Holmes EW, Chandrasekhar AJ, McCabe M, Radvany R, Garrity ER. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999, 159:829-833.
16. Monforte V, Lopez C, Santos F, Zurbano F, De La Torre M, Sole A, Gavalda J, Ussetti P, Lama R, Cifrian J, Borro JM, Pastor A, Len O, Bravo C, Roman A. A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-Seropositive lung transplant recipients. Am J Transplant 2009, 9:1134-1141.
17. Valentine VG, Weill D, Gupta MR, Raper B, LaPlace SG, Lombard GA, Bonvillain RW, Taylor DE, Dhillon GS. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 2008, 27:875-881.
18. Zamora MR, Nicolls MR, Hodges TN, Marquesen J, Astor T, Grazia T, Weill D. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004, 4:1635-1642.
19. Chmiel C, Speich R, Hofer M, Michel D, Mertens T, Weder W, Boehler A. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008, 46:831-839.
20. Jaksch P, Zweytick B, Kerschner H, Hoda AM, Keplinger M, Lang G, Aigner C, Klepetko W. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant 2009, 28:670-675.
21. Palmer SM, Limaye AP, Banks M, Gallup D, Chapman J, Lawrence EC, Dunitz J, Milstone A, Reynolds J, Yung GL, Chan KM, Aris R, Garrity E, Valentine V, McCall J, Chow SC, Davis RD, Avery R. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010, 152:761-769.
22. Finlen Copeland CA, Davis WA, Snyder LD, Banks M, Avery R, Davis RD, Palmer SM. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant 2011, 30:990-996.
23. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002, 185:20-27.
24. Bhorade SM, Lurain NS, Jordan A, Leischner J, Villanueva J, Durazo R, Creech S, Vigneswaran WT, Garrity ER. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002, 21:1274-1282.
25. Swarup R, Allenspach LL, Nemeh HW, Stagner LD, Betensley AD. Timing of basiliximab induction and development of acute rejection in lung transplant patients. J Heart Lung Transplant 2011, 30:1228-1235.
26. Thomas LD, Milstone AP, Miller GG, Loyd JE, Dummer JS. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen. Clin Transplant 2009, 23:476-483.
27. Mitsani D, Nguyen MH, Kwak EJ, Silveira FP, Vadnerkar A, Pilewski J, Crespo M, Toyoda Y, Bermudez C, Clancy CJ. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis. J Heart Lung Transplant 2010, 29:1014-1020.
28. Tamm M, Aboyoun CL, Chhajed PN, Rainer S, Malouf MA, Glanville AR. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004, 170:1120-1123.